Satu Mustjoki
Satu Mustjoki
Verified email at helsinki.fi - Homepage
Title
Cited by
Cited by
Year
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3
T Mäkinen, T Veikkola, S Mustjoki, T Karpanen, B Catimel, EC Nice, ...
The EMBO journal 20 (17), 4762-4773, 2001
9752001
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
HLM Koskela, S Eldfors, P Ellonen, AJ van Adrichem, H Kuusanmäki, ...
New England Journal of Medicine 366 (20), 1905-1913, 2012
6302012
VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells
P Salven, S Mustjoki, R Alitalo, K Alitalo, S Rafii
Blood, The Journal of the American Society of Hematology 101 (1), 168-172, 2003
5012003
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
K Porkka, P Koskenvesa, T Lundán, J Rimpiläinen, S Mustjoki, R Smykla, ...
Blood 112 (4), 1005-1012, 2008
3932008
Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
SE Flanagan, E Haapaniemi, MA Russell, R Caswell, HL Allen, ...
Nature genetics 46 (8), 812-814, 2014
3662014
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia
A Jerez, MJ Clemente, H Makishima, H Koskela, F LeBlanc, K Peng Ng, ...
Blood, The Journal of the American Society of Hematology 120 (15), 3048-3057, 2012
3242012
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S Mustjoki, M Ekblom, TP Arstila, I Dybedal, PK Epling-Burnette, F Guilhot, ...
Leukemia 23 (8), 1398-1405, 2009
3232009
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia
T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ...
Cancer discovery 3 (12), 1416-1429, 2013
312*2013
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ...
The Lancet Oncology 19 (6), 747-757, 2018
2602018
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
HLM Rajala, S Eldfors, H Kuusanmäki, AJ Van Adrichem, T Olson, ...
Blood, The Journal of the American Society of Hematology 121 (22), 4541-4550, 2013
2452013
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
A Giustacchini, S Thongjuea, N Barkas, PS Woll, BJ Povinelli, CAG Booth, ...
Nature medicine 23 (6), 692, 2017
2342017
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia
B Simonsson, T Gedde-Dahl, B Markevärn, K Remes, J Stentoft, ...
Blood, The Journal of the American Society of Hematology 118 (12), 3228-3235, 2011
2082011
Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3
EM Haapaniemi, M Kaustio, HLM Rajala, AJ van Adrichem, L Kainulainen, ...
Blood 125 (4), 639-648, 2015
1972015
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
A Kreutzman, V Juvonen, V Kairisto, M Ekblom, L Stenke, R Seggewiss, ...
Blood, The Journal of the American Society of Hematology 116 (5), 772-782, 2010
1812010
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M Ilander, U Olsson-Strömberg, H Schlums, J Guilhot, O Brück, ...
Leukemia 31 (5), 1108-1116, 2017
1502017
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy
S Mustjoki, N Sidenius, CFM Sier, F Blasi, E Elonen, R Alitalo, A Vaheri
Cancer research 60 (24), 7126-7132, 2000
1212000
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients
A Jerez, MJ Clemente, H Makishima, H Rajala, I Gómez-Seguí, T Olson, ...
Blood 122 (14), 2453-2459, 2013
1162013
Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia
L Christiansson, S Söderlund, E Svensson, S Mustjoki, M Bengtsson, ...
PloS one 8 (1), e55818, 2013
1092013
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A Kreutzman, K Ladell, C Koechel, E Gostick, M Ekblom, L Stenke, T Melo, ...
Leukemia 25 (10), 1587-1597, 2011
952011
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ...
Leukemia 28 (8), 1738-1742, 2014
922014
The system can't perform the operation now. Try again later.
Articles 1–20